Pepteligence
Share
Medical notice — For research and educational purposes only. Not medical advice. Consult a licensed physician before using any peptide or compound.

Tirzepatide

metabolicweight-lossfat-loss
Regulatory status — FDA-approved for indicated use

Tirzepatide is a once-weekly injectable dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, approved for the treatment of type 2 diabetes and obesity. Clinical trial programs (SURPASS, SURMOUNT) demonstrate dose-dependent reductions in HbA1c and body weight, along with broad cardiometabolic benefits including improvements in blood pressure, lipids, and waist circumference. Evidence strength for glycemic and weight outcomes is among the highest available for any incretin-based therapy.

Evidence coverage

44/62 claims verified by independent fact-checker.

5 claims pending coverage
  • Evidence tier below threshold(4 claims)
  • FDA prescribing-label data(1 claim)

Pepteligence regenerates entries quarterly and when new high-tier evidence appears.

Quick facts

Half-life
5 days
Typical dose
5-15mg/wk SC
Route
subcutaneous
Frequency
Once weekly [3]
Cycle length
ongoing
Evidence strength
Phase III RCTs

Suggested labs for this peptide class — educational reference only; not medical advice.

Official prescribing information

The following sections are reproduced from the FDA-approved prescribing information. This is the authoritative clinical record — not editorial content.

Approved use(s)

® MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.

Dosing & administration

The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control. After 4 weeks, increase the…

Warnings & precautions

In both sexes of rats, tirzepatide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) in a 2-year study at clinically relevant plasma exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including m…

Contraindications

MOUNJARO is contraindicated in patients with: A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. Serious hypersensitivity react…

Drug interactions

5.3. When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia MOUNJARO delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral…

Adverse reactions

The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-cell Tumors Acute Pancreatitis Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin Hypersensitivity Reactions Acute Kidney Injury Due to Volume Depletion Sever…

Source: FDA-approved prescribing information for Mounjaro, last updated January 21, 2026. View original at DailyMed →

TL;DR

  • Half-life: 5 days — dosed once weekly.
  • Administered via subcutaneous.
  • Evidence base: randomised controlled trials.
  • Primary goals: metabolic, weight-loss, fat-loss.
EVIDENCE HIERARCHYRCTsObservationalAnimal studiesAnecdotal

Randomised controlled trials

How we evaluate evidence →

How it works

GHRH analogues stimulate pulsatile GH release from the pituitary, elevating IGF-1 and promoting fat oxidation.

Tirzepatide is a synthetic peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), representing a mechanistic advance over selective GLP-1R agonists [1] [17]. GLP-1R activation stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central nervous system pathways [18]. GIPR agonism adds complementary metabolic effects; animal studies indicate that GIPR agonist activity produces distinct metabolic outcomes compared to GIPR antagonism, suggesting that the agonist configuration used in tirzepatide is mechanistically important for its weight and insulin-sensitizing profile [19]. Mechanistic data from a meta-analytic study indicate that tirzepatide produces greater improvement in insulin sensitivity per unit of weight lost compared to semaglutide, an effect not fully explained by weight reduction alone [2]. In humans with obesity or overweight and prediabetes or normoglycemia, a post-hoc analysis from the SURMOUNT-1 trial found that tirzepatide improved both β-cell function and insulin sensitivity over 72 weeks [20]. Animal studies suggest tirzepatide may reverse early β-cell dedifferentiation in diabetic models independently of weight loss effects [21]. Mechanistic studies in high-fat diet-induced obesity models indicate that tirzepatide-mediated weight loss is associated with favorable changes in gut microbiota composition [22]. Preclinical evidence also points to potential neuroinflammatory and brain insulin signaling effects through dual GIP/GLP-1R activation, though these findings remain animal-model-level and are not established in humans [23].

What the research says

Research summary content coming soon. Check the references section for indexed studies.

100%50%25%0%00h1t½0h2t½0h3t½0h4t½0h
Approximate plasma concentration over 4 half-lives (0h × 4 = 0h)

Protocol lifecycle

BeforeDuringAfter

Before — Pre-cycle readiness

Readiness checklist

Medical evaluation
  • Confirmed diagnosis of type 2 diabetes or obesity meeting approved indication criteria
  • Baseline metabolic panel: HbA1c, fasting glucose, lipids, renal function, liver enzymes
  • Assessment for contraindicated conditions (personal/family history of medullary thyroid carcinoma, MEN2)
  • Review of current medications for potential interactions, particularly insulin secretagogues (hypoglycemia risk) and insulin (dose adjustment may be required) [7]
Product safety
  • Confirm use of FDA-approved formulation; avoid compounded tirzepatide/B12 products due to identified impurity concerns [11]
  • Verify cold-chain storage compliance for subcutaneous pen
Lifestyle preparation
  • Establish or review structured resistance exercise plan to support lean mass preservation during expected weight loss [10]
  • Review dietary protein targets; adequate intake supports lean mass retention during active weight loss
  • Consider Mediterranean dietary pattern; observational data suggest additive benefit on insulin resistance beyond weight loss [16]
Perioperative planning
  • Notify surgical team of tirzepatide use prior to elective procedures given preliminary signals regarding wound outcomes in reconstructive surgery [15]
  • Confirm indication and absence of contraindications, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (class-level GLP-1R agonist concern; not tirzepatide-specific signal in this packet)
  • Establish baseline HbA1c, fasting glucose, renal function, lipid panel, and body weight to track treatment response [6]
  • Avoid use of compounded tirzepatide/B12 combination products, which have been shown to contain impurities absent from FDA-approved formulations [11]
  • Discuss perioperative planning with surgical team if elective surgery is anticipated, given preliminary signals regarding postoperative wound outcomes with GLP-1 receptor agonist use [15]

During — Active protocol

Protocol notice — The following describes common protocols reported in research and community sources. This is not medical advice. Dosing, frequency, and duration should be determined with a licensed physician familiar with peptide research.
  • Phase 3 trial programs initiated dosing at 2.5 mg/week for 4 weeks before escalating, with further titration to 5 mg, 10 mg, or 15 mg once weekly; dose-dependent weight loss and HbA1c reduction were observed across all active doses [3]
  • Monitor for gastrointestinal adverse events, particularly during dose escalation phases [14]
  • A randomized controlled trial protocol (LEAN-PREP) is evaluating resistance exercise combined with adequate protein intake to mitigate lean mass loss during therapy; individuals at risk for sarcopenia should consider structured resistance training [10]
  • Observational data suggest that Mediterranean diet adherence during tirzepatide therapy may produce additive improvements in insulin resistance and adiposity indices beyond weight loss alone [16]
  • Monitor for signs of ketoacidosis, particularly in individuals with type 1 diabetes or those with significant carbohydrate restriction; a FAERS database signal has been identified [13]

After — Post-cycle

  • Real-world cohort data suggest that persistence with tirzepatide therapy drives cumulative cardiometabolic and kidney-metabolic benefits; discontinuation has been associated with loss of these improvements [5]
  • Long-term cardiovascular outcome data beyond the SURPASS and SURMOUNT trial durations are not yet available; post-treatment durability of weight loss and glycemic benefit requires ongoing monitoring
  • Reassess cardiometabolic risk factors at treatment end and plan for continued lifestyle modification or pharmacotherapy to sustain achieved outcomes [6]

Stacks it appears in

Tirzepatide + Resistance exercise and protein supplementation (to mitigate lean mass loss) [src:0c779ad2-eb5d-46b6-bf66-e61bb7e8a75c]
TirzepatideResistance exercise and protein supplementation (to mitigate lean mass loss) [src:0c779ad2-eb5d-46b6-bf66-e61bb7e8a75c]
metabolic
Tirzepatide + Mediterranean diet adherence (observational data suggest additive benefit on insulin resistance and adiposity indices beyond weight loss alone) [src:ba98748b-d955-4528-980a-2358ba262be2]
TirzepatideMediterranean diet adherence (observational data suggest additive benefit on insulin resistance and adiposity indices beyond weight loss alone) [src:ba98748b-d955-4528-980a-2358ba262be2]
metabolic

Related peptides

Other compounds indexed on Pepteligence that share research tags with Tirzepatide. Educational context only.

Semaglutide

Tier 1
metabolicweight-lossfat-loss

Tesamorelin

Tier 1
metabolicfat-loss

Liraglutide

Tier 1
metabolicweight-loss

MOTS-c

Tier 3
metabolic

Safety

Common side effects

  • ·Nausea — most frequent during dose escalation phases; lower short-term rate reported for tirzepatide versus semaglutide in a real-world nationwide cohort [14]
  • ·Vomiting — reported across SURPASS and SURMOUNT trial programs [6]
  • ·Diarrhea — gastrointestinal class effect of incretin-based therapies [14]
  • ·Decreased appetite — central and peripheral mechanism contributing to weight loss [18]

Rare side effects

  • ·Hailey-Hailey disease remission has been anecdotally reported in a case report; mechanism and generalizability are unknown [24]
  • ·Altered postoperative wound outcomes in patients undergoing free flap breast reconstruction — preliminary signal from a mechanistic study [15]
Safety notice — Serious / theoretical risks:
  • Drug-induced ketoacidosis — disproportionality signal identified in FAERS database analysis; at-risk populations and mechanism not yet characterized [13]
  • Acute pancreatitis — class-level concern for GLP-1 receptor agonists noted in mechanistic context; no tirzepatide-specific signal identified in this research packet [25]

Contraindications

  • ·Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (class-level GLP-1R agonist label concern; regulatory primary source not included in current research packet)
  • ·Known hypersensitivity to tirzepatide or any component of the formulation
  • ·Compounded tirzepatide/B12 combination products — associated with peptide-related impurities not present in FDA-approved formulations; safety profile unknown [11]
  • ·Use with caution in individuals at elevated risk of ketoacidosis (e.g., very low carbohydrate diets, concurrent insulin use with aggressive dose reduction, type 1 diabetes off-label use) given FAERS signal [13]
  • ·Preoperative and perioperative period for major reconstructive surgery — preliminary signals suggest altered wound healing; discuss timing with surgical team [15]

Community experiences

Community content — User-submitted experiences are self-reported and have not been verified. They do not constitute medical advice. Pepteligence aggregates community data under Section 230 protections.

No community experiences yet for Tirzepatide. Be the first to share yours.

Share your experience →

Have you tried Tirzepatide?

Share your protocol and outcome to help build the community dataset.

Share your experience →

Tirzepatide — at a glance

PropertyTirzepatide—
Half-life5 days—
Routesubcutaneous—
Typical dose5-15mg/wk SC—
MechanismTirzepatide is a synthetic peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), representing a mechanistic advance over selective GLP-1R agonists. GLP-1R activation stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central nervous system pathways. GIPR agonism adds complementary metabolic effects; animal studies indicate that GIPR agonist activity produces distinct metabolic outcomes compared to GIPR antagonism, suggesting that the agonist configuration used in tirzepatide is mechanistically important for its weight and insulin-sensitizing profile. Mechanistic data from a meta-analytic study indicate that tirzepatide produces greater improvement in insulin sensitivity per unit of weight lost compared to semaglutide, an effect not fully explained by weight reduction alone. In humans with obesity or overweight and prediabetes or normoglycemia, a post-hoc analysis from the SURMOUNT-1 trial found that tirzepatide improved both β-cell function and insulin sensitivity over 72 weeks. Animal studies suggest tirzepatide may reverse early β-cell dedifferentiation in diabetic models independently of weight loss effects. Mechanistic studies in high-fat diet-induced obesity models indicate that tirzepatide-mediated weight loss is associated with favorable changes in gut microbiota composition. Preclinical evidence also points to potential neuroinflammatory and brain insulin signaling effects through dual GIP/GLP-1R activation, though these findings remain animal-model-level and are not established in humans.—
Evidence strengthrctanecdotal
Primary goalmetabolic—

Frequently asked questions

What is tirzepatide?
Tirzepatide is a once-weekly injectable synthetic peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It is FDA-approved and sold under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for obesity).
How does tirzepatide work?
Tirzepatide activates both GIPR and GLP-1R, which together stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through central nervous system pathways. Its dual-receptor mechanism is a mechanistic advance over selective GLP-1R agonists.
What is tirzepatide FDA-approved for?
Tirzepatide (Mounjaro) is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients with type 2 diabetes. Tirzepatide (Zepbound) is approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
What are the brand names for tirzepatide?
Tirzepatide is sold as Mounjaro (for type 2 diabetes) and Zepbound (for obesity and weight management), both manufactured by Eli Lilly. Both are subcutaneous injectable formulations dosed once weekly.
What is the typical dosage of tirzepatide?
Clinical trial programs (SURPASS, SURMOUNT) used doses of 5 mg, 10 mg, and 15 mg administered once weekly subcutaneously, with gradual titration to the target dose. Dosing decisions should be made in consultation with a physician.
How long until tirzepatide starts working?
Effects on blood glucose and appetite can be observed within the first weeks of treatment. Meaningful weight loss typically accumulates over months of continued therapy — clinical trial programs measured outcomes over 40–72 weeks of treatment.
What are common side effects of tirzepatide?
The most commonly reported side effects with GLP-1/GIP receptor agonists include nausea, vomiting, diarrhea, constipation, and reduced appetite — predominantly gastrointestinal. These are most pronounced during dose escalation and typically diminish over time.
Who should not take tirzepatide?
Tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), and in those with known hypersensitivity to tirzepatide or any component of the formulation.
Is compounded tirzepatide safe?
Compounded tirzepatide products (including tirzepatide/B12 combinations) have been associated with peptide-related impurities not present in FDA-approved formulations. The safety profile of compounded versions is unknown. FDA-approved Mounjaro and Zepbound are the only formulations with established clinical evidence.
Can tirzepatide be combined with other compounds?
Research has examined resistance exercise and protein supplementation as adjuncts to mitigate lean mass loss during tirzepatide therapy. Observational data suggest additive benefit from Mediterranean diet adherence on insulin resistance beyond weight loss alone. Combining tirzepatide with other glucose-lowering agents requires physician supervision.
How long do people take tirzepatide?
Tirzepatide is indicated for chronic, ongoing use. Clinical trials evaluated it over 40–72 weeks, and weight regain after discontinuation has been observed in weight-management data. Treatment duration should be determined in consultation with a physician.
What is the difference between tirzepatide and semaglutide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist; semaglutide is a selective GLP-1 receptor agonist. Real-world comparative data suggest tirzepatide produces greater weight loss on average, though both are FDA-approved and carry similar GLP-1 class contraindications (MTC/MEN2 history). Individual response varies.

References

  1. [1]

    The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.

    Fisman Enrique Z, Tenenbaum Alexander

    Cardiovascular diabetology · 2021 · PMID 34819089

    View on PubMed →
  2. [2]

    Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.

    Mather Kieren J, Mari Andrea, Weerakkody Govinda et al.

    Diabetes, obesity & metabolism · 2025 · PMID 39762971

    View on PubMed →
  3. [3]

    Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program.

    Nicholls Stephen J, Tofé Santiago, le Roux Carel W et al.

    Cardiovascular diabetology · 2024 · PMID 38341541

    View on PubMed →
  4. [4]

    Shifts in body mass index category with tirzepatide and associated changes in cardiometabolic risk factors in people with obesity: a post hoc analysis from the SURMOUNT-1 and SURMOUNT-4 trials.

    Sattar Naveed, Lee Clare J, Srinath Reshmi et al.

    American journal of preventive cardiology · 2026 · PMID 42006438

    View on PubMed →
  5. [5]

    Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates.

    Rangraze Imran Rashid, El-Tanani Mohamed, Janez Andrej et al.

    Diabetes therapy · 2026 · PMID 42029986

    View on PubMed →
  6. [6]

    Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes.

    Aminorroaya Arya, Oikonomou Evangelos K, Biswas Dhruva et al.

    Journal of the American College of Cardiology · 2025 · PMID 40368575

    View on PubMed →
  7. [7]

    Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real-World Evidence.

    Acucella Giuseppina Alessia, Caponio Danilo

    Endocrinology, diabetes & metabolism · 2026 · PMID 42007544

    View on PubMed →
  8. [8]

    Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.

    Malhotra Atul, Grunstein Ronald, Azarbarzin Ali et al.

    Nature medicine · 2026 · PMID 41540105

    View on PubMed →
  9. [9]

    Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives.

    Fiorucci Stefano, Urbani Ginevra

    Expert opinion on investigational drugs · 2025 · PMID 40782123

    View on PubMed →
  10. [10]

    LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial.

    Alawadhi Ameenah A, Alroudhan Dherar, Alsaeed Dalal J et al.

    BMJ open · 2026 · PMID 42020128

    View on PubMed →
  11. [11]

    A novel, widespread impurity in mass-compounded tirzepatide/b12 products: patient safety implications.

    Jordan Brad, Arbogast Luke, Clemens Matthew et al.

    Expert opinion on drug safety · 2026 · PMID 42010938

    View on PubMed →
  12. [12]

    Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on cardiovascular-kidney-metabolic stage progression: a real-world cohort study.

    Wu Jheng-Yan, Lee Keng-Wei, Huang Sheng-Chi et al.

    Diabetes research and clinical practice · 2026 · PMID 42009260

    View on PubMed →
  13. [13]

    Drug-Associated Ketoacidosis: A Comprehensive Disproportionality Analysis Based on the FAERS Database.

    Du Pengqiang, Chen Xiaoyu, Xu Yinpeng et al.

    Diabetes, obesity & metabolism · 2026 · PMID 42010884

    View on PubMed →
  14. [14]

    Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study.

    Hepşen Sema, Haymana Cem, Ertepe Küçükgöde Gizem et al.

    Obesity facts · 2026 · PMID 42030208

    View on PubMed →
  15. [15]

    GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction.

    Ha Joy, Lester Ethan, De May Henning et al.

    Journal of reconstructive microsurgery · 2026 · PMID 42013898

    View on PubMed →
  16. [16]

    Mediterranean diet adherence and tirzepatide: real-world evidence on adiposity indices and insulin resistance beyond weight loss.

    Paternò Valentina, Geraci Giulio, Piticchio Tommaso et al.

    Frontiers in endocrinology · 2025 · PMID 41613958

    View on PubMed →
  17. [17]

    Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.

    Muzurović Emir M, Volčanšek Špela, Tomšić Karin Zibar et al.

    Journal of cardiovascular pharmacology and therapeutics · 2022 · PMID 36546652

    View on PubMed →
  18. [18]

    GLP-1-based medications: Mechanisms involved in obesity treatment.

    Salvador Javier

    Medicina clinica · 2025 · PMID 40466247

    View on PubMed →
  19. [19]

    A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice.

    Davies Iona, Turland Alexandra, Tran Hanh Duyen et al.

    Diabetes, obesity & metabolism · 2026 · PMID 41287212

    View on PubMed →
  20. [20]

    Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial.

    Mari Andrea, Stefanski Adam, van Raalte Daniel H et al.

    Diabetes care · 2025 · PMID 40694530

    View on PubMed →
  21. [21]

    Effect of Weight-Neutral Treatment With Semaglutide or Tirzepatide on β-Cell Identity in db/db Mice.

    Deng Zhaobin, Zheng Dongxu, Son Jinsook et al.

    Acta physiologica (Oxford, England) · 2026 · PMID 41354136

    View on PubMed →
  22. [22]

    The role of gut microbiota in Tirzepatide-mediated alleviation of high-fat diet-induced obesity.

    Wang Ruonan, Lin Zijing, He Mingjie et al.

    European journal of pharmacology · 2025 · PMID 40516844

    View on PubMed →
  23. [23]

    A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease.

    Alshehri Ghadah H, Al-Kuraishy Hayder M, Al-Gareeb Ali I et al.

    European journal of pharmacology · 2025 · PMID 40706971

    View on PubMed →
  24. [24]

    Rapid remission of Hailey-Hailey disease with tirzepatide therapy: A case report.

    Velusamy Breethiga, Sokumbi Olayemi, Latimer Benjamin L et al.

    JAAD case reports · 2026 · PMID 42011394

    View on PubMed →
  25. [25]

    Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs).

    Li Jiaxun, Liang Jizhou, Zhang Wei et al.

    Diabetes therapy · 2026 · PMID 42012593

    View on PubMed →
  26. [?]

    Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes.

    Yamaguchi Yuko, Kuwata Hitoshi, Imura Masahiro et al.

    Diabetologia · 2025 · PMID 40694059

    View on PubMed →
  27. [?]

    GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies.

    Boccatonda Andrea, D'Ardes Damiano, Brighenti Alice et al.

    Diabetes research and clinical practice · 2026 · PMID 42009258

    View on PubMed →
  28. [?]

    Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy.

    Shah Jui, Makwana Bhargav, Panchal Krisha et al.

    American journal of ophthalmology · 2026 · PMID 42025665

    View on PubMed →

Compare Tirzepatide with…

Semaglutide vs Tirzepatide

Semaglutide · Tirzepatide

View comparison →